What is Aptevo Therapeutics?
Headquartered in Seattle, Aptevo Therapeutics is a pioneer in the development of bispecific and trispecific immunotherapies. The company leverages its proprietary ADAPTIR and ADAPTIR-FLEX platforms to engineer sophisticated protein therapeutics designed to elicit robust immune responses against malignant cells. Its primary focus remains on addressing high-unmet needs in blood cancers and solid tumors, with its lead candidate, mipletamig, currently undergoing rigorous Phase 1b/2 clinical evaluation. By integrating advanced antibody engineering with clinical-stage execution, Aptevo occupies a specialized niche in the biotechnology sector, aiming to redefine treatment paradigms for acute myeloid leukemia and other complex oncological conditions.
How much funding has Aptevo Therapeutics raised?
Aptevo Therapeutics has raised a total of $48.5M across 4 funding rounds:
Debt
$35M
Other Financing Round
$2M
Share Placement
$2M
Grant
$1.5M
Debt (2016): $35M with participation from MidCap Financial
Share Placement (2025): $2M, investors not publicly disclosed
Other Financing Round (2025): $2M, investors not publicly disclosed
Grant (2026): $1.5M, investors not publicly disclosed
Key Investors in Aptevo Therapeutics
MidCap Financial
MidCap Financial is a middle-market-focused finance firm that provides flexible, asset-based lending solutions to support the growth and operational needs of healthcare and life sciences companies.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Aptevo Therapeutics?
With the recent influx of capital, Aptevo Therapeutics is well-positioned to advance its clinical pipeline and optimize its ADAPTIR-FLEX technology. The strategic focus will likely center on the successful completion of ongoing Phase 1b/2 trials for mipletamig, while simultaneously expanding the reach of its multispecific antibody candidates. As the company navigates the complexities of late-stage drug development, the current financial stability allows for increased investment in manufacturing scalability and potential collaborative partnerships. Investors will be closely monitoring the firm's ability to translate its innovative protein engineering into tangible clinical outcomes, which remains the primary catalyst for future valuation growth and long-term market viability.
See full Aptevo Therapeutics company page
